Vaccine Contract Manufacturing Market, 2016 - 2026

Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Vaccine Contract Manufacturing Market, 2016 - 2026" report to their offering.

The "Vaccine Contract Manufacturing Market, 2016 - 2026" report provides an extensive study of the current market landscape of CMOs focused on vaccines. The study presents an in-depth analysis of a diverse set of biopharmaceutical CMOs based on key parameters such as geographical location, scale of operation, use of expression systems and manufacturing capabilities. In addition, it captures some of the potential growth areas that will likely present tremendous opportunities for vaccine CMOs and contribute to an accelerated pace of growth.

The report assesses the key drivers that have governed the evolution of vaccine contract manufacturing market over the past several years, along with an elaborate discussion on the future trends that are likely to shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for vaccine CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions.

The study also provides information on some of the most important aspects of vaccine outsourcing; these include growing collaborations, investment activity, facility expansions and technological advances. In addition to some of the well-known benefits and a promising outlook, the study highlights considerable challenges that are currently prevalent in the market. Examples include quality concerns, stringent regulations and lack of funding. Nevertheless, these challenges are resulting in new strategies and technological improvements, which are likely to prove advantageous in the long run.

The base year for the report is 2016; it provides market forecasts for the period 2016 - 2026. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Example Highlights

- Vaccine development and manufacturing, characterized by complex production processes and high entry barriers, is set in a highly regulated market landscape. Outsourcing has emerged as a rising trend in this domain and gained a lot of traction in the last few years. As the market continues to evolve, CMOs are rapidly enhancing their service offering to offer end-to-end services to their clients.
- Developed regions, such as North America and Europe, currently dominate the vaccine contract manufacturing market. Of the 79 CMOs we identified, 41 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, 20 CMOs have facilities located in Germany, France and the UK alone.
- CMOs in emerging locations have also gained ground. With increasing support from local governments, many low-income geographies have restructured their indigenous regulatory landscape. Intellectual property protection laws have been made more stringent in favor of foreign sponsors looking to outsource business operations in the same regions. Established players in this market have also received the necessary qualifications and certifications to provide services in compliance with global standards.
- Out of 79 CMOs, 21 offer end-to-end services across preclinical, clinical and commercial scale. We observed a rapid adoption of mammalian and insect production technologies among service providers.
- The highly competitive market landscape is abuzz with partnership activity. We have identified 128 unique partnerships that were inked in the recent past. Of these, a sizeable proportion (25%) is mergers / acquisitions. We believe this trend is likely to continue in the future.
- Technological advances are amongst the major driving factors in this market. The introduction of novel expression systems, such as the EB66® and GPEx® cell lines, and cell culture media platforms have sustained the interest of players in this field. Single use / disposable technologies, a key bio-manufacturing trend, are also becoming more and more popular among contract manufacturers. This is representative of the current market intensity.
- Driven by increasing global demand and the rapidly expanding vaccine market, we expect the overall contract manufacturing market in this space to grow at an annualized rate of 9.8%. The rate of growth is likely to vary significantly across different segments / activities and across geographical regions.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Competitive Landscape

5. Vaccine Contract Manufacturing: Developed Regions

6. Vaccine Contract Manufacturing: Emerging Regions

7. Recent Developments

8. Market Forecast

9. Swot Analysis

10. Future Trends

11. Conclusion

12. Interview Transcripts

13. Appendix I Tabulated Data

14. Appendix II List Of Companies And Organizations

- 3P Biopharmaceuticals
- ABL
- Acambis
- Accugenix
- Actavis
- Advanced BioScience Laboratories
- Advaxis
- Aeras
- Air Force Hospital, Guangzhou
- AJ Biologics
- Albany Molecular Research (AMRI)
- Alexion
- Algonomics
- Altaris Capital Partner
- AmbioPharm
- AnaSpec
- Aptuit
- Association for Assessment and Accreditation of Laboratory Animal Care
- Association Sportive du Golf Club Val de l'Indre
- Australian Therapeutic Goods Administration
- Avid Bioservices
- Bachem
- Batavia Biosciences
- Bavarian Nordic
- Baxter BioPharma Solutions
- BD Biosciences
- Benchmark Vaccines
- Bharat Biotech
- Bill and Melinda Gates Foundation
- BioCell Corporation
- Biocon
- BioConnections
- BioConvergence
- Biofabri
- Bioline Group of Companies
- Biological E
- BioMARC
- Biomay
- Biomedical Advanced Research and Development Authority
- BioMotiv
- Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research
- BioReliance Holdings
- BioTechnique
- Biotechnology and Biological Sciences Research Council
- Biotechnology and Biological Sciences Research Council
- Biovest International
- Boehringer Ingelheim
- Boehringer Ingelheim BioXcellence
- Bristol-Myers Squibb
- Bryllan
- CALIXAR
- Canadian Animal Health Institute
- Canadian Council on Animal Care
- Catalent
- Catalent Pharma Solutions
- Celsis International
- Centers for Disease Control and Prevention
- CEPiA Sanofi (Transgene)
- Cetus Corporation
- CEVEC Pharmaceuticals
- Charles River Laboratories International
- Chimera Biotec
- China Agricultural University
- China National Biotec Group
- Chinese Center for Disease Control and Prevention
- Cobra Biologics
- Cook Pharmica
- Council of the Chinese University of Hong Kong
- Crucell Sweden
- Cytovance Biologics
- Daiichi Sankyo
- Deltamune
- Developing Countries Vaccine Manufacturers Network
- Dr. Reddy's Laboratories
- Emergent BioSolutions
- Engineering and Physical Sciences Research Council
- Eubiologics
- Eurogentec
- European Medicines Agency
- Federation of Indian Chambers of Commerce and Industry
- Florida Biologix
- Friedrich-Loeffler-Institut
- FUJIFILM Diosynth Biotechnologies
- Gallant Custom Laboratories
- Gamma Vaccines
- Genentech
- GENEWIZ
- GlaxoSmithKline
- Global Alliance for Vaccines and Immunizations
- GNH India
- Goodwin Biotechnology
- Government of India's Universal Immunisation Programme
- Grand River Aseptic Manufacturing
- GreenPak Biotech
- Guangxi Veterinary Research Institute
- Haffkine Institute
- HALIX
- Harbin Veterinary Research Institute
- Harbin Veterinary Research Institute, China
- HK Jockey Club Charities Trust
- HLL Biotech
- Hong Kong Institute of Biotechnology
- IDT Biologika
- Immune Design
- Immune Targeting Systems
- ImmunoSite Technologies
- ImVisioN Therapeutics
- Index Ventures
- Indian Council of Medical Research
- Indian Immunologicals
- Infectious Disease Research Institute
- Innovation & Technology Commission, HKSAR Government, China
- Integrity Bio
- Intercell
- International Medica Foundation
- International Society for Pharmaceutical Engineering
- Interros Group
- Inviragen
- Irvine Pharmaceutical Services
- Jubilant HollisterStier
- KABS Pharmaceutical Services
- Kaneka Corporation
- KBI Biopharma
- LigoCyte Pharmaceuticals
- Lonza
- Magellan Biosciences
- MassBiologics
- Medicago
- Mefar Ilac (Birgi Mefar Group)
- Meridian Life Science
- Ministry of Health & Family Welfare, Government of India
- Mitsubishi Gas Chemical Company
- Mitsubishi Tanabe Pharma Corporation
- Moderna Therapeutics
- Mymetics Corporation
- National Avian Influenza Reference Laboratory
- National Heart, Lung and Blood Institute
- National Institutes of Allergy and Infectious Diseases
- Norwegian Institute of Public Health
- Novartis
- Novasep
- Novavax
- NPO Petrovax Pharm
- NTC
- OctoPlus
- Okairos
- Oncotest
- Organization for Economic Cooperation and Development
- OSO Biopharmaceuticals Manufacturing (OsoBio)
- Pacific GMP
- Panacea Biotec
- Paragon Bioservices
- PATH
- Pfenex
- Pfizer
- Pfizer CentreOne
- Pharmapak
- PharmaSynth
- Premas Biotech
- Prime European Therapeuticals
- ProBioGen
- Protagen
- PX'Therapeutics
- QuiaPEG
- RAFAGEN
- Recipharm
- Richter-Helm
- Riemser Pharma
- SAFC
- Sanofi
- Sanofi Pasteur
- Sartorius Stedim Biotech
- Serum Institute
- Shandong Zhaoxin Bio-tech Company
- Shanghai Laboratory Animal Commission
- ShangPharma
- Sigma-Aldrich
- South China Agricultural University
- Statens Serum Institut
- Stellar Biotechnologies
- Swiss State Secretariat Education, Research and Innovation
- SynCo Bio Partners
- Technology Strategy Board
- Temasek Life Sciences Ventures
- The College of Animal Science and Technology, Sichuan Agricultural University, China
- Thermo Fisher Scientific
- Tianjin CanSino Biotechnology
- UK Medicines Control Agency
- Unitech Pharma Group
- United States Food and Drug Association
- Univercells
- University of Maryland
- University of Oxford
- University of Pennsylvania
- Upperton
- Vaccibody
- Vacsera
- Valneva
- Vetter Pharma International
- VGXI
- Vibalogics
- Vivalis
- Vybion (Recombinant Protein Technologies and Products)
- Waisman Biomanufacturing
- Walter Reed Army Institute of Research - Pilot Bioproduction Facility
- Wellcome Trust
- WIL Research
- World Trade Organization
- WuXi AppTec
- Zoetis

For more information visit http://www.researchandmarkets.com/research/wkztks/vaccine_contract

Sector: Vaccines

                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                    
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716